MAGEA3 and cutaneous melanoma: Despite the null clinical efficacy of a vaccine encompassing recombinant MAGE-A3 together with an immunostimulant (AS15), which was tested in two comprehensive randomized, double-blinded, placebo-controlled phase III clinical trials in patients with completely resected stage IB, II, and IIIA MAGE-A3-positive NSCLC (MAGRIT) [64] and in patients with completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma (DERMA) [65], other formulations of this CTA are proving to be more effective.